XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

XTalks

JANUARY 5, 2021

The test identifies SARS-CoV-2 protein fragments from nasal swab samples. AI is expected to make significant strides in the life science and healthcare sectors in 2021. AI approaches can also be useful in developing personalized and precision medicines. 3. Artificial Intelligence. AI and Neuroscience.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

Drug Discovery World

FEBRUARY 20, 2024

The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 52

Marketing Drugs Life Science Genome 52

Pharmaceutical Technology

APRIL 18, 2023

Innovation S-curve for the pharmaceutical industry HIV peptides is a key innovation area in pharmaceuticals HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products.

Protein 147

Protein Vaccination Vaccine Production 147

Pharmaceutical Technology

MARCH 10, 2023

Personalised medicines will also be developed at the centre. The opening of this new facility plays into the UK government’s Life Sciences Industrial Strategy. Operations at the CBC will focus on building plasmids , viral vectors and recombinant proteins for the production of cell and gene therapies.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

Roots Analysis

JANUARY 28, 2024

Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Drug Discovery World

FEBRUARY 5, 2024

The launches include an integrated solution suite for liquid biopsy workflows, and the Resolvex i300 and antibody purification columns AffinEx Protein A Capture, adding biomarker discovery, drug development and personalised medicine research to proteomics workflows.

Gene Therapy 65

Gene Therapy Life Science Production Dermatology 65

Scienmag

FEBRUARY 5, 2021

Membrane-localized phage proteins may also help revitalize, enhance existing antibiotics A study from the Center for Phage Technology, part of Texas A&M’s College of Agriculture and Life Sciences and Texas A&M AgriLife Research, shows how the “hidden” genes in bacteriophages — types of viruses that infect and destroy (..)

Gene 74

Gene Bacteria Life Science Development 74

pharmaphorum

OCTOBER 4, 2022

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025. This is due to close concurrently with the merger.

Gene Therapy 114

Gene Therapy Gene Life Science Genetics 114

XTalks

FEBRUARY 19, 2024

In a recent study published by Weill Cornell Medicine in the Journal of Infectious Diseases , researchers have reported the potential of Moderna’s experimental mRNA vaccine in protecting adults against CMV, which could potentially also stop the transmission of the virus from mothers to their infants during pregnancy.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Drug Discovery World

DECEMBER 14, 2023

The new centre represents a flagship investment within the University’s Glasgow Riverside Innovation District (GRID) and will be home to commercial businesses as well as the University of Glasgow-led Living Laboratory for Precision Medicine.

Drugs 76

Drugs Life Science Research Scientist 76

Drug Discovery World

APRIL 27, 2023

The report notes that the focus on science and pharma throughout the Covid-19 pandemic has resulted in the emergence of new locations as life science hubs and name checks Boston, Massachusetts and San Francisco, California as examples of centres with heightened investment appeal in the life sciences 1.

Life Science 52

Life Science Drugs Research Gene Splicing 52

XTalks

JULY 20, 2022

The production facility will be equipped to develop and manufacture plasmid DNA, nucleic acids, recombinant proteins and other therapeutics produced through methods involving microbial fermentation. The company broke ground on the facility in April this year and is on track to complete construction by the end of the third quarter in 2023.

Vaccination 105

Vaccination Vaccine Manufacturing Life Science 105

Drug Discovery World

JANUARY 23, 2024

The annual Genesis conference took place at the end of 2023 in London, bringing together key opinion leaders, investors and innovators from across the life sciences sector to exchange insights, debate trends and generate deals. What would Alexandra Gray like from the life sciences industry?

Life Science 59

Life Science Business Development Protein Development 59

XTalks

OCTOBER 12, 2021

14-3-3 zeta) protein, which the UToledo researchers had been studying for its role in immune-related pathologies, such as aortic aneurysms and in signaling pathways involving the pro-inflammatory cytokine interleukin-17. However, they found the opposite to be true, where the protein was actually protective against development of the disease.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Drug Discovery World

OCTOBER 26, 2023

To enable Evotec’s precision medicine approach, we have been building technology platforms that allow PanOmics or multi-omics data generation at an industrialised scale. The technologies cover the whole range of biomolecules from genes to protein to metabolites. This article is sponsored by Evotec.

Drugs 52

Drugs Protein Genome Genomics 52

Scienmag

NOVEMBER 2, 2020

“The protein alpha-synuclein is thought to play a central role in neurodegenerative diseases, and is one of the most investigated targets for developing diagnostics and therapies for Parkinson’s disease,” explains Hilal Lashuel, director of the Lashuel lab at EPFL’s School of Life Sciences.

Life Science 50

Life Science Protein Development Engineer 50

XTalks

JANUARY 26, 2023

Tyrosine Kinase Inhibitors for Cancer Treatment Tyrosine kinases, or TKs, are a group of signaling molecules that affect multiple downstream proteins. Results from the ALPINE study have been published in the New England Journal of Medicine. As with many cancers, CLL and SLL are more difficult to treat in the relapse/refractory setting.

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

XTalks

JANUARY 3, 2024

Polydefkis, professor of Neurology at Johns Hopkins University School of Medicine and an investigator in the Phase III NEURO-TTRansform study on which Wainua’s FDA approval was grounded on, in the news release. The accumulation of TTR fibrils disrupts the usual functions of these tissues.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

Pharmaceutical Technology

OCTOBER 5, 2022

More commonly in life sciences, for example, acquisitions are used to access new markets more easily. increase between 2020 and 2021, and life sciences accounts for 2.4% From 2019–21, there have been 16 life sciences FDI projects in Scotland. In Scotland, foreign direct investment (FDI) projects saw a 28.1%

Life Science 130

Life Science Development Medicine Doctors 130

Drug Discovery World

MAY 11, 2023

Fundraising and investment are a core pillar of not just BioTrinity events but of the drug discovery industry at large, so events such as Tuesday’s keynote, Investment Trends for the Life Sciences Industry, are critical for members of the industry.

Life Science 52

Life Science Genetics Vaccination Vaccine 52

Drug Discovery World

MAY 5, 2023

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

Protein 52

Protein Life Science Sales Production 52

Drug Discovery World

APRIL 28, 2023

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

Protein 52

Protein Life Science Sales Production 52

Delveinsight

JULY 29, 2021

TNB-585 complements Amgen’s existing prostate cancer portfolio, including acapatamab (formerly AMG 160), a half-life extended, PSMA-targeted BiTE; and AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, which is both in phase 1. Details on the pipeline are still very thin.

Drugs 98

Drugs Protein Life Science Trials 98

Drug Discovery World

APRIL 21, 2023

In another presentation, Dr Hengshuo Liu from ACROBiosystems will examine the areas where proteins and innovation are advancing biomedicine. What you will learn:  What is the next phase of cancer immunotherapy and what should researchers be focusing on to move to this next step? 

Life Science 52

Life Science Protein Sales Production 52

XTalks

AUGUST 26, 2020

. “We found that macrophage programming is driven by more than the immune system — it is also driven by the environment in which the macrophages reside,” said lead study author Asrar Malik, the UIC Schweppe Family Distinguished Professor and head of pharmacology and regenerative medicine at the College of Medicine.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

Drug Discovery World

APRIL 21, 2023

In another presentation, Dr Hengshuo Liu from ACROBiosystems will examine the areas where proteins and innovation are advancing biomedicine. What you will learn:  What is the next phase of cancer immunotherapy and what should researchers be focusing on to move to this next step? 

Life Science 52

Life Science Protein Sales Production 52

Drug Discovery World

JULY 11, 2023

Tim Lowery , President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. So, where do we go from here to realise their potential in life sciences?

Big Data 40

Big Data Development Life Science Drugs 40

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. My initial exposure to medicine came through bench research.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

Drug Discovery World

OCTOBER 16, 2023

Indeed, this is bolstered by top tier universities like Newcastle University, which specialises in structure-based approaches for drug discovery, developing innovative technologies that support the identification of new medicines, and is well-established in cancer drug discovery. Government investment of £1.3

Drugs 76

Drugs Life Science Gene Therapy Genome 76

pharmaphorum

JANUARY 11, 2023

To find potential drug candidates, disease-associated protein targets are tested against a small pool of less than ten million distinct chemotypes synthesised at great effort and expense over the past 100 years. He enjoys building fundamental science-based solutions to major business problems that impact society. About the interviewee.

Big Data 122

Big Data Drugs Clinical Trials Clinical Trials 122

XTalks

DECEMBER 20, 2021

Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Covovax is a protein subunit vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine demonstrated an overall efficacy of 90.4

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

Drug Discovery World

OCTOBER 20, 2023

Its proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis. Through the purchase, Thermo Fisher will also gain a library of more than 5,300 validated protein biomarker targets.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

XTalks

MAY 9, 2024

As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

XTalks

JULY 14, 2022

For example, when T cells (a type of white blood cells that fight off infections and cancer) are activated in our immune systems, thousands of proteins in these cells change. The proteins are interconnected and changes in one protein level can impact that of another.

Gene 98

Gene Regulation Protein Gene Editing 98

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

JULY 10, 2023

UCB specializes in the discovery and development of innovative medicines for severe diseases that affect the immune system or central nervous system. In the case of gMG, certain autoantibodies target specific proteins on the post-synaptic membrane of the neuromuscular junction, thereby impairing synaptic transmission.

FDA Approval 98

FDA Approval Antibody Protein Engineer 98